ArticleCureus2026
Prevalence and Associated Echocardiographic Findings of Pulmonary Hypertension in Chronic Kidney Disease: A Cross-Sectional Study.
Article in Cureus, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundPulmonary hypertension (PH) is an increasingly recognized cardiovascular complication in chronic kidney disease (CKD), yet the echocardiographic features associated with its presence remain insufficiently characterized in routine nephrology practice. This study determined the prevalence of echocardiographically defined PH in CKD and examined echocardiographic variables associated with its presence. METHODOLOGY: This cross-sectional study included 120 adults with stages 3-5 CKD, including both conservatively managed patients and those receiving maintenance hemodialysis, evaluated between November 2024 and December 2025. PH was defined echocardiographically as an estimated pulmonary artery systolic pressure (PASP) >35 mmHg. Clinical, renal, and echocardiographic variables were compared between patients with and without PH. Because the estimated PASP was derived from tricuspid regurgitation velocity (TRV) and estimated right atrial pressure (RAP), these variables were considered definitional components of PH classification rather than independent associated findings. Exploratory analyses focused on non-definitional clinical and echocardiographic variables.
resultsPH was present in 68 (56.7%) patients, while 52 (43.3%) had no PH. Mild PH was observed in 21 (17.5%), moderate PH in 25 (20.8%), and severe PH in 22 (18.3%). Patients with PH more frequently had stage 5 CKD (40, 58.8%, vs. 14, 26.9%), dialysis dependence (38, 55.9%, vs. 16, 30.8%), volume overload (41, 60.3%, vs. 16, 30.8%), and diastolic dysfunction (53, 77.9%, vs. 22, 42.3%). Among non-definitional echocardiographic findings, patients with PH had lower tricuspid annular plane systolic excursion, larger right atrial diameter, and more frequent diastolic dysfunction. TRV and estimated RAP were not interpreted as independent associated variables because they contributed directly to PASP estimation.
conclusionsPH was present in 68 of 120 patients with CKD, corresponding to a prevalence of 56.7%. Because PH was classified using estimated PASP derived from TRV and estimated RAP, these variables were not interpreted as independent echocardiographic correlates. Non-definitional echocardiographic findings associated with PH included lower tricuspid annular plane systolic excursion, larger right atrial size, and more frequent diastolic dysfunction. These findings support careful multiparameter echocardiographic assessment in CKD but should be interpreted as associative rather than predictive evidence.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.